Tibulizumab - Zura Bio
Alternative Names: Anti-BAFF IL-17A monoclonal antibody - Eli Lilly and Company; BAFF/IL-17A-Eli-Lilly and Company; LY-3090106; ZB-106Latest Information Update: 02 Jun 2025
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; Zura Bio
- Class Anti-inflammatories; Antirheumatics; Bispecific antibodies; Skin disorder therapies; Small molecules
- Mechanism of Action B cell activating factor inhibitors; Interleukin 17 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hidradenitis suppurativa; Systemic scleroderma
- Phase I Rheumatoid arthritis; Sjogren's syndrome